Scott Reents
Executive VP & CFO at AbbVie
We now expect SKYRIZI global revenues of $16,500,000,000 an increase of $600,000,000 reflecting share gains in psoriasis and IBD RINVOQ global sales of $8,200,000,000 an increase of $300,000,000 reflecting momentum across all approved indications. US HUMIRA revenues of 3,500,000,000 a decrease of $500,000,000 reflecting higher erosion from biosimilar competition, as well as further molecule compression. Botox Therapeutic global sales of $3,600,000,000 an increase of 100,000,000 reflecting growth in chronic migraine and other indications. Total oral CGRP revenues of $2,200,000,000 an increase of $100,000,000 reflecting strong prescription demand. IMBRUVICA global revenues of $2,800,000,000 an increase of $100,000,000 reflecting lower erosion.